International Journal of Gastroenterology and Hepatology (ISSN: 2995-2301) | Volume 2, Issue 2 | Case Report | Open Access

Promising Result with The Use of Immunotherapy to Treat Lynch Syndrome

Tamene Yonas*

Rajasekaran Vedika, Tamene Yonas*, John French, Lydia Tesfaye

Wellstar Kennestone Regional Hospital, USA

*Correspondence to: Tamene Yonas 

Fulltext PDF


A 38-year-old male initially presented with complaints of abdominal pain with extensive history of changes in bowel habits. The patient's medical history included a prior motor vehicle accident and hypertension. After the patient presenting with complaining of Abdominal pain in ED A CT of abdomen was performed showing a necrotic appearing mass inseparable from the sigmoid colon and left hydroureteronephrosis that was treated with a 26cm double- J ureteral stent. He was also had a biopsy which revealed a poorly differentiated sigmoid colon adenocarcinoma, classified as at least stage IIIC after staging was complete/. Given the extent of the tumor, he was initially deemed unrespectable by surgical oncology. The tumor was MSI-unstable with loss of MSH2 protein. He was thus started on Dostarlimab 500mg given IV every 3 weeks. After 6 cycles of therapy, there was significant tumor response allowing for en bloc resection of his cancer. Final pathology showed a complete response to therapy and no viable tumor was noted. This was consistent with a pathological complete response (pCR). He has remained on Dostarlimab and will complete 1 year of therapy as recommended by our GI tumor board without significant complications.


Immunotherapy; Lynch Syndrome


Rajasekaran Vedika, Tamene Yonas, John French, Lydia Tesfaye.Promising Result with The Use of Immunotherapy to Treat Lynch Syndrome. Int Jour Gastro Hepat. 2023;2(2):1-2.